Skip to content

Study · Randomized controlled trial · 2026

12 results

Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.

Shukla AP, Dunn JP, Gomez Valderas E, Fraseur Brumm J, Karanikas CA, Hunter Gibble T

Diabetes, obesity & metabolism4 Nov 2025Cited by 8 (Europe PMC)

PMID41187971 (opens in a new tab)PMCIDPMC12673425 (opens in a new tab)DOI10.1111/dom.70215 (opens in a new tab)PepBankPUB-41187971
Read at sourcePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity without T2D, tirzepatide improved SF-36v2 Physical Component Summary scores from baseline at Week 72.

    In plain wordsIn adults with obesity, physical quality-of-life scores improved from baseline with tirzepatide after 72 weeks.

    Peptide
    Tirzepatide
    Outcome
    IncreaseSF-36v2 Physical Component Summary score change at Week 72
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    At Week 72, PCS scores improved from baseline with both treatments (p < 0.001).
    1 context sentence
    Summary · context
    This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity without T2D, semaglutide improved SF-36v2 Physical Component Summary scores from baseline at Week 72.

    In plain wordsIn adults with obesity, physical quality-of-life scores improved from baseline with semaglutide after 72 weeks.

    Peptide
    Semaglutide
    Outcome
    IncreaseSF-36v2 Physical Component Summary score change at Week 72
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    At Week 72, PCS scores improved from baseline with both treatments (p < 0.001).
    1 context sentence
    Summary · context
    This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity without T2D, tirzepatide did not significantly change SF-36v2 Mental Component Summary scores from baseline at Week 72.

    In plain wordsIn adults with obesity, mental quality-of-life scores did not change significantly from baseline with tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeSF-36v2 Mental Component Summary score change at Week 72
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    However, MCS scores did not show significant improvements from baseline (p > 0.05 for both treatment arms).
    1 context sentence
    Summary · context
    This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity without T2D, semaglutide did not significantly change SF-36v2 Mental Component Summary scores from baseline at Week 72.

    In plain wordsIn adults with obesity, mental quality-of-life scores did not change significantly from baseline with semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeSF-36v2 Mental Component Summary score change at Week 72
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    However, MCS scores did not show significant improvements from baseline (p > 0.05 for both treatment arms).
    1 context sentence
    Summary · context
    This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity without T2D, all SF-36v2 domain scores improved from baseline with tirzepatide.

    In plain wordsIn adults with obesity, every quality-of-life domain score improved from baseline with tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseSF-36v2 domain scores change at Week 72
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    All domain scores improved (p ≤ 0.008)
    1 context sentence
    Summary · context
    This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with obesity without T2D, all SF-36v2 domain scores improved from baseline with semaglutide.

    In plain wordsIn adults with obesity, every quality-of-life domain score improved from baseline with semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseSF-36v2 domain scores change at Week 72
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    All domain scores improved (p ≤ 0.008)
    1 context sentence
    Summary · context
    This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with obesity without T2D, tirzepatide improved the SF-36v2 General Health score more than semaglutide.

    In plain wordsIn adults with obesity, general health scores improved more with tirzepatide than with semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseSF-36v2 General Health score change at Week 72
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose · 72 weeksAs given in this study (human).

    Measurements

    General Health score change
    5.45 points
    tirzepatide
    General Health score change
    4.2 points
    semaglutide

    Source sentences

    Summary
    greater improvements in General Health (GH) with tirzepatide versus semaglutide (5.45 vs. 4.20; p = 0.003)
    1 context sentence
    Summary · context
    This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In participants with limited baseline physical function, tirzepatide improved the Physical Component Summary score more than semaglutide.

    In plain wordsIn people with limited physical function, physical quality-of-life scores improved more with tirzepatide than with semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreasePhysical Component Summary change in participants with limited physical function
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Participants with limited physical function improved in PCS, Physical Functioning (PF), and GH with tirzepatide versus semaglutide (p ≤ 0.025).
    1 context sentence
    Summary · context
    This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In participants with limited baseline physical function, tirzepatide improved the Physical Functioning score more than semaglutide.

    In plain wordsIn people with limited physical function, physical functioning scores improved more with tirzepatide than with semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreasePhysical Functioning score change in participants with limited physical function
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Participants with limited physical function improved in PCS, Physical Functioning (PF), and GH with tirzepatide versus semaglutide (p ≤ 0.025).
    1 context sentence
    Summary · context
    This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In participants with limited baseline physical function, tirzepatide improved the General Health score more than semaglutide.

    In plain wordsIn people with limited physical function, general health scores improved more with tirzepatide than with semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseGeneral Health score change in participants with limited physical function
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Quality of life · Whole body
    Studied dose
    maximum tolerated dose · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Participants with limited physical function improved in PCS, Physical Functioning (PF), and GH with tirzepatide versus semaglutide (p ≤ 0.025).
    1 context sentence
    Summary · context
    This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 11HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In adults with obesity without T2D, higher body weight reduction was associated with more SF-36v2 improvement in pooled tirzepatide and semaglutide recipients.

    In plain wordsIn adults with obesity, losing more weight was linked to bigger quality-of-life gains in people on tirzepatide or semaglutide combined.

    Peptide
    Tirzepatide
    Outcome
    IncreaseSF-36v2 improvement by body weight reduction threshold
    Study

    n: not reported in source

    Comparator
    Lower body weight reduction
    Outcome group
    Quality of life · Whole body

    Source sentences

    Summary
    Higher BW reductions were associated with more improvement in PCS, PF, Role-Physical, Bodily Pain (BP), GH, and Vitality scores with tirzepatide and semaglutide (pooled).
    1 context sentence
    Summary · context
    This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  2. 12HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with obesity without T2D, higher body weight reduction was associated with more SF-36v2 improvement in pooled tirzepatide and semaglutide recipients.

    In plain wordsIn adults with obesity, losing more weight was linked to bigger quality-of-life gains in people on tirzepatide or semaglutide combined.

    Peptide
    Semaglutide
    Outcome
    IncreaseSF-36v2 improvement by body weight reduction threshold
    Study

    n: not reported in source

    Comparator
    Lower body weight reduction
    Outcome group
    Quality of life · Whole body

    Source sentences

    Summary
    Higher BW reductions were associated with more improvement in PCS, PF, Role-Physical, Bodily Pain (BP), GH, and Vitality scores with tirzepatide and semaglutide (pooled).
    1 context sentence
    Summary · context
    This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.